Greenwich LifeSciences Inc. (GLSI), a clinical-stage biopharmaceutical company developing an immunotherapy to prevent breast cancer recurrences, has a clinical trial update to watch this month.
The company is scheduled to report preliminary delayed-type-hypersensitivity immune response results from the open-label arm of its ongoing phase 3 Flamingo-01 study at the upcoming AACR Meeting on April 20, 2026.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.